Hyperactivity Disorders in Adults Controlled with Long Acting Stimulants

Release Date: 13-Nov-2020

It has been found that the action of long-acting stimulants can improve the overall safety in the patients suffering from hyperactivity disorders. A group of researchers researched about the activity of 2 long-acting psychostimulants in the overall driving of the patients suffering from hyperactivity disorders. A total of 44 patients were enrolled in the study. It was a randomized as well as double-bling cross over procedure which included the introduction of dose-optimized controlled-release methylphenidate PRC-063 (45, 70, or 100 mg/day) or lisdexamfetamine (30, 50, or 70 mg/day).


It was observed by the researchers that one daily introduction of lisdexamfetamine led to the some of the comparable effects in driving the performance of young adults suffering from hyperactivity disorder. Improved routine care, increase in average DMW driver. The driving response was observed after 1, 9, 12 and 15 hours post-dose. It has also been found more than neuro-typical peers, vehicular collisions are the reasons for high adolescent morbidity and mortality. As per a clinical research randomized controlled trial conducted by a group of investigators, ADHD symptoms improved more with lisdexamfetamine when compared with other ADHD medications such as methylphenidate.

Need custom market research solution? We can help you with that too.